메뉴 건너뛰기




Volumn 93, Issue 1, 2011, Pages 91-98

Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia

Author keywords

Glucocorticoids; ITP; Rituximab; Treg cells

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; DANAZOL; DEXAMETHASONE; GLUCOCORTICOID; HYDROCORTISONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROMETHAZINE; RITUXIMAB; VINCRISTINE;

EID: 78751580375     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0753-z     Document Type: Article
Times cited : (89)

References (22)
  • 1
    • 37149028925 scopus 로고    scopus 로고
    • Immune-mediated thrombocytopenias: Focus on chronic immune thrombocyto-penic purpura
    • 10.1053/j.seminhematol.2007.11.001
    • R McMillan 2007 Immune-mediated thrombocytopenias: focus on chronic immune thrombocyto-penic purpura Semin Hematol 44 1 2 10.1053/j.seminhematol. 2007.11.001
    • (2007) Semin Hematol , vol.44 , pp. 1-2
    • McMillan, R.1
  • 2
    • 34547106040 scopus 로고    scopus 로고
    • Immune thrombocytopenic purpura
    • 10.1016/j.hoc.2007.06.007 17666288
    • B Psaila JB Bussel 2007 Immune thrombocytopenic purpura Hematol Oncol Clin North Am 21 743 759 10.1016/j.hoc.2007.06.007 17666288
    • (2007) Hematol Oncol Clin North Am , vol.21 , pp. 743-759
    • Psaila, B.1    Bussel, J.B.2
  • 3
    • 51649127854 scopus 로고    scopus 로고
    • Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura
    • 1:CAS:528:DC%2BD1cXpvVOktLw%3D 10.1182/blood-2008-01-135335 18420827
    • J Yu S Heck V Patel J Levan Y Yu JB Bussel, et al. 2008 Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura Blood 112 1325 1328 1:CAS:528:DC%2BD1cXpvVOktLw%3D 10.1182/blood-2008-01-135335 18420827
    • (2008) Blood , vol.112 , pp. 1325-1328
    • Yu, J.1    Heck, S.2    Patel, V.3    Levan, J.4    Yu, Y.5    Bussel, J.B.6
  • 4
    • 16844365788 scopus 로고    scopus 로고
    • Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self
    • 1:CAS:528:DC%2BD2MXisVyitLY%3D 10.1038/ni1178 15785760
    • S Sakaguchi 2005 Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self Nat Immunol 6 345 352 1:CAS:528:DC%2BD2MXisVyitLY%3D 10.1038/ni1178 15785760
    • (2005) Nat Immunol , vol.6 , pp. 345-352
    • Sakaguchi, S.1
  • 5
    • 38349128561 scopus 로고    scopus 로고
    • Is splenectomy still the gold standard for the treatment of chronic ITP?
    • 10.1002/ajh.21109 17994550
    • F Rodeghiero M Ruggieri 2008 Is splenectomy still the gold standard for the treatment of chronic ITP? Am J Hematol 83 91 10.1002/ajh.21109 17994550
    • (2008) Am J Hematol , vol.83 , pp. 91
    • Rodeghiero, F.1    Ruggieri, M.2
  • 6
    • 38349124539 scopus 로고    scopus 로고
    • Splenectomy for immune thrombocytopenic purpura: Surgery for the 21st century
    • 10.1002/ajh.21029 17722078
    • JP Dolan BC Sheppard TG Deloughery 2008 Splenectomy for immune thrombocytopenic purpura: surgery for the 21st century Am J Hematol 83 93 96 10.1002/ajh.21029 17722078
    • (2008) Am J Hematol , vol.83 , pp. 93-96
    • Dolan, J.P.1    Sheppard, B.C.2    Deloughery, T.G.3
  • 7
    • 0345337254 scopus 로고    scopus 로고
    • Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
    • 1:CAS:528:DyaK1cXlsFCgu7c%3D 9704735
    • P McLaughlin AJ Grillo-López BK Link R Levy MS Czuczman ME Williams, et al. 1998 Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol 16 2825 2833 1:CAS:528:DyaK1cXlsFCgu7c%3D 9704735
    • (1998) J Clin Oncol , vol.16 , pp. 2825-2833
    • McLaughlin, P.1    Grillo-López, A.J.2    Link, B.K.3    Levy, R.4    Czuczman, M.S.5    Williams, M.E.6
  • 9
    • 33846918681 scopus 로고    scopus 로고
    • Systematic review: Efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura
    • 17200219
    • DM Arnold F Dentali MA Crowther RM Meyer RJ Cook C Sigouin, et al. 2007 Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura Ann Intern Med 146 25 33 17200219
    • (2007) Ann Intern Med , vol.146 , pp. 25-33
    • Arnold, D.M.1    Dentali, F.2    Crowther, M.A.3    Meyer, R.M.4    Cook, R.J.5    Sigouin, C.6
  • 10
    • 33750291236 scopus 로고    scopus 로고
    • Treatment of pemphigus vulgaris with rituximab and intravenous immuneglobulin
    • 1:CAS:528:DC%2BD28XhtFCisLrN 10.1056/NEJMoa062930 17065638
    • AR Ahmed Z Spigelman LA Cavacini MR Posner 2006 Treatment of pemphigus vulgaris with rituximab and intravenous immuneglobulin N Engl J Med 355 1772 1779 1:CAS:528:DC%2BD28XhtFCisLrN 10.1056/NEJMoa062930 17065638
    • (2006) N Engl J Med , vol.355 , pp. 1772-1779
    • Ahmed, A.R.1    Spigelman, Z.2    Cavacini, L.A.3    Posner, M.R.4
  • 11
    • 70349916130 scopus 로고    scopus 로고
    • Should low-dose mycophenolate mofetil be used to prolong the response after rituximab therapy in patients with immune thrombocytopenic purpura? A case report
    • 1:CAS:528:DC%2BD1MXhtFOju7zP 10.1179/102453309X439782 19635186
    • Q Bruserud K Havardstein 2009 Should low-dose mycophenolate mofetil be used to prolong the response after rituximab therapy in patients with immune thrombocytopenic purpura? A case report Hematology. 14 224 226 1:CAS:528:DC%2BD1MXhtFOju7zP 10.1179/102453309X439782 19635186
    • (2009) Hematology. , vol.14 , pp. 224-226
    • Bruserud, Q.1    Havardstein, K.2
  • 12
    • 72149125317 scopus 로고    scopus 로고
    • Clinical applications of intravenous immunoglobulins (IVIg) beyond immunodeficiencies and neurology
    • 1:CAS:528:DC%2BD1MXhsFejsbbE 10.1111/j.1365-2249.2009.04024.x 19883421
    • HP Hartung L Mouthon R Ahmed S Jordan KB Laupland S Jolles 2009 Clinical applications of intravenous immunoglobulins (IVIg) beyond immunodeficiencies and neurology Clin Exp Immunol 158 23 33 1:CAS:528:DC%2BD1MXhsFejsbbE 10.1111/j.1365-2249.2009.04024.x 19883421
    • (2009) Clin Exp Immunol , vol.158 , pp. 23-33
    • Hartung, H.P.1    Mouthon, L.2    Ahmed, R.3    Jordan, S.4    Laupland, K.B.5    Jolles, S.6
  • 13
    • 77950974675 scopus 로고    scopus 로고
    • Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia
    • 1:CAS:528:DC%2BC3cXkvFKiurc%3D 10.1182/blood-2009-07-229815 20130241
    • F Zaja M Baccarani P Mazza M Bocchia L Gugliotta A Zaccaria, et al. 2010 Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia Blood 115 2755 2762 1:CAS:528:DC%2BC3cXkvFKiurc%3D 10.1182/blood-2009-07-229815 20130241
    • (2010) Blood , vol.115 , pp. 2755-2762
    • Zaja, F.1    Baccarani, M.2    Mazza, P.3    Bocchia, M.4    Gugliotta, L.5    Zaccaria, A.6
  • 14
    • 64049085194 scopus 로고    scopus 로고
    • Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group
    • 1:CAS:528:DC%2BD1MXjsFKhurs%3D 10.1182/blood-2008-07-162503 19005182
    • F Rodeghiero R Stasi T Gernsheimer M Michel D Provan DM Amold, et al. 2009 Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group Blood 113 2386 2393 1:CAS:528:DC%2BD1MXjsFKhurs%3D 10.1182/blood-2008-07-162503 19005182
    • (2009) Blood , vol.113 , pp. 2386-2393
    • Rodeghiero, F.1    Stasi, R.2    Gernsheimer, T.3    Michel, M.4    Provan, D.5    Amold, D.M.6
  • 15
    • 44949126978 scopus 로고    scopus 로고
    • Low dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura
    • 1:CAS:528:DC%2BD1cXhsVWlur7O 10.3324/haematol.12206 18403395
    • F Zaja ML Battista MT Pirrotta S Palmieri M Montagna N Vianelli, et al. 2008 Low dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura Haematologica 93 930 933 1:CAS:528:DC%2BD1cXhsVWlur7O 10.3324/haematol.12206 18403395
    • (2008) Haematologica , vol.93 , pp. 930-933
    • Zaja, F.1    Battista, M.L.2    Pirrotta, M.T.3    Palmieri, S.4    Montagna, M.5    Vianelli, N.6
  • 16
    • 33846925496 scopus 로고    scopus 로고
    • Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: A GIMEMA experience
    • 1:CAS:528:DC%2BD2sXjt1CgsrY%3D 10.1182/blood-2005-12-015222 17077333
    • MG Mazzucconi P Fazi S Bernasconi G De Rossi G Leone L Gugliotta, et al. 2007 Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience Blood 109 1401 1407 1:CAS:528:DC%2BD2sXjt1CgsrY%3D 10.1182/blood-2005-12-015222 17077333
    • (2007) Blood , vol.109 , pp. 1401-1407
    • Mazzucconi, M.G.1    Fazi, P.2    Bernasconi, S.3    De Rossi, G.4    Leone, G.5    Gugliotta, L.6
  • 17
    • 66749173745 scopus 로고    scopus 로고
    • Corticosteroid side effects and risk for bleeding in immune thrombocytopenic purpura: Patient and hematologist perspectives
    • 10.1111/j.1600-0609.2009.01265.x 19374704
    • JA Guidry JN George SK Vesely SM Kennison DR Terrell 2009 Corticosteroid side effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives Eur J Haematol 83 175 182 10.1111/j.1600-0609. 2009.01265.x 19374704
    • (2009) Eur J Haematol , vol.83 , pp. 175-182
    • Guidry, J.A.1    George, J.N.2    Vesely, S.K.3    Kennison, S.M.4    Terrell, D.R.5
  • 18
    • 40949154401 scopus 로고    scopus 로고
    • Rituximab in the treatment of autoimmune haematological disorders
    • 1:CAS:528:DC%2BD1cXlsV2muro%3D 10.1111/j.1365-2141.2008.07054.x 18318765
    • B Garvey 2008 Rituximab in the treatment of autoimmune haematological disorders Br J Haematol 141 149 169 1:CAS:528:DC%2BD1cXlsV2muro%3D 10.1111/j.1365-2141.2008.07054.x 18318765
    • (2008) Br J Haematol , vol.141 , pp. 149-169
    • Garvey, B.1
  • 19
    • 0032740187 scopus 로고    scopus 로고
    • Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma
    • 10561020
    • AJ Grillo-López CA White C Varns D Shen A Wei A McClure, et al. 1999 Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma Semin Oncol 26 66 73 10561020
    • (1999) Semin Oncol , vol.26 , pp. 66-73
    • Grillo-López, A.J.1    White, C.A.2    Varns, C.3    Shen, D.4    Wei, A.5    McClure, A.6
  • 20
    • 34447098797 scopus 로고    scopus 로고
    • Multistep pathogenesis of autoimmune disease
    • 1:CAS:528:DC%2BD2sXotlGmtr0%3D 10.1016/j.cell.2007.06.033 17632054
    • CC Goodnow 2007 Multistep pathogenesis of autoimmune disease Cell 130 25 35 1:CAS:528:DC%2BD2sXotlGmtr0%3D 10.1016/j.cell.2007.06.033 17632054
    • (2007) Cell , vol.130 , pp. 25-35
    • Goodnow, C.C.1
  • 21
    • 51649091745 scopus 로고    scopus 로고
    • Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab
    • 1:CAS:528:DC%2BD1cXpvVOktr8%3D 10.1182/blood-2007-12-129262 18375792
    • R Stasi N Cooper G Del Poeta E Stipa M Laura Evangelista E Abruzzese, et al. 2008 Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab Blood 112 1147 1150 1:CAS:528:DC%2BD1cXpvVOktr8%3D 10.1182/blood-2007-12-129262 18375792
    • (2008) Blood , vol.112 , pp. 1147-1150
    • Stasi, R.1    Cooper, N.2    Del Poeta, G.3    Stipa, E.4    Laura Evangelista, M.5    Abruzzese, E.6
  • 22
    • 62949099499 scopus 로고    scopus 로고
    • Slow responses to standard dose rituximab in immune thrombocytopenic purpura
    • 10.3324/haematol.2008.001396 19252177
    • K Kelly M Glesson PT Murphy 2009 Slow responses to standard dose rituximab in immune thrombocytopenic purpura Haematologica 94 443 444 10.3324/haematol.2008.001396 19252177
    • (2009) Haematologica , vol.94 , pp. 443-444
    • Kelly, K.1    Glesson, M.2    Murphy, P.T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.